With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...
CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...
Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...
Management reaffirmed guidance for fiscal 2025, expecting revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency. CSL Behring is anticipated to sustain ...
CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results